All News

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

The most popular content from our Asembia coverage largely covered biosimilars.

A retrospective study found that instances of recurrent pulmonary hypertension due to vascular reocclusion or restenosis were extremely uncommon after balloon pulmonary angioplasty.

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.

This qualitative study conducted interviews with caregivers of patients with spinal muscular atrophy (SMA) to explore their unique experiences and challenges in navigating health systems to access disease-modifying therapies.

This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.

The most popular reimbursement content of 2023 included coverage of the shift from the Oncology Care Model to the Enhancing Oncology Model, reactions to the 2024 Medicare Physician Fee Schedule, and concerns around denial of services in Medicare Advantage plans.

The study authors note that the Best Asthma Control Test for School Children and Adolescents (Best ACT-S) complements a previously developed questionnaire that assesses preschool-aged patients with asthma.

The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.

The top psoriasis articles included topics on new therapies for the treatment of psoriasis in adults.

Health care workers who received SARS-CoV-2 vaccinations were found to be protected against declines in respiratory parameters after overcoming COVID-19, highlighting the importance of COVID-19 vaccines for health care workers.

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

In this study, 52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.

Through interviews and contributed content, Strategic Alliance Partnerships provide insights into changes in health care delivery and medicine.

A recent study encapsulates how patients and caregivers characterize the impact of Duchenne muscular dystrophy (DMD) on patients’ physical limitations and symptom burden, potentially helping to inform patient-centered strategies for assessing clinical outcomes in DMD research.

Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.

The most-read rare disease articles include topics on increasing research and awareness on genetic and nongenetic rare diseases.

Our most-viewed videos include interviews about a type 2 diabetes reversal program with impressive 6-month results, concerns over service denials in certain health plans, the Enhancing Oncology Model, and more.

While the Enhancing Oncology Model is the successor of the Oncology Care Model, it includes some very real challenges for participating practices, explained Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network.

In a new study, patients with psoriasis had a 39.46% prevalence of being overweight and 37.41% prevalence of obesity—83.56% patients also dismissed the importance of having healthy balanced eating habits.

This year’s most-read articles on atopic dermatitis (AD) explored different treatment and education methods.

The top coverage from this year’s Academy of Managed Care Pharmacy (AMCP) 2023 conference includes interviews on managed care policy, ophthalmic drugs, and formulary management, as well as health plan best practices.

The top 5 most-read dermatology content of 2023 included topics in melanoma, acne scarring, hidradenitis suppurativa, chronic kidney disease, hyperhidrosis, and infertility rates.

Patients with spinal muscular atrophy (SMA) treated with a more expensive medication were found to have higher pharmacy costs but lower SMA-related health care resource utilization and medical costs compared with patients receiving standard-of-care nusinersen monotherapy.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.

An analysis study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The top 5 articles about rare blood featured information on pseudo–thrombotic thrombocytopenic purpura (TTP), immune TTP, and hemophilia.

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

The most-read articles in digital health covered improved outcomes, patient management, and reduced cost of care in telehealth and app-based care.